← Leaderboards
David S. Silberstein
Biomimetix Jv, Llc
$2,300,000
Attributed
$2,300,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2018–22$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,300,000 · 1
By mechanism
R44$2,300,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Animal Model”
- Ted Ross · University Of Georgia$71,962,304
- Leonard Freedman · Leidos Biomedical Research, Inc.$64,938,611
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$45,644,409
- Steven A. Ackerman · University Of Wisconsin-Madison$38,898,438
- Gary Fanger · Rise Therapeutics, Llc$16,982,327
Research focus
Animal ModelBaseBlood - Brain Barrier AnatomyBmx GeneBrainBrain NeoplasmsCancer PatientChemistryChemoradiationChemotherapyClinical TrialsCognitionCommercializationCommon TreatmentCostCranial IrradiationDeath RateDementiaDesignDeteriorationDiffuseDistantDoseDrug Efficacy
Grant awards (4)
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.$600,000
R44 · FY2022 · CA · contact PI
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.$400,000
R44 · FY2021 · CA · contact PI
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.$1,000,000
R44 · FY2020 · CA · contact PI
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.$300,000
R44 · FY2018 · CA · contact PI